title: Early and late onset side effects of short-acting insulin analogue in seven Japanese diabetic patients.
abstract: Short-acting insulin analogue has previously shown to be equal to short-acting human regular insulin regarding in vitro characteristics, immunogenicity, and safety. But in the present study, we experienced seven patients who had mild to moderate side effects due to short-acting insulin analogue. These side effects could be divided into two types based on the appearance time; one with early onset and the other with late onset. Early onset side effects include rash, disturbances in walking and general fatigue that can not be explained by the swing in glucose levels. These symptoms appeared 2-3 days after the use of short-acting insulin analogue and disappeared several hours after switching short-acting human regular insulin. The late onset side effect is bilateral leg edema, which appeared 1-2 months after the induction of short-acting insulin analogue and disappeared after several hours by changing to short-acting human regular insulin. We should monitor the early and late onset side effects as diligently as possible when we use short-acting insulin analogue on diabetic patients.
authors.affiliation: Division of Diabetes and Clinical Nutrition, Kansai-Denryoku Hospital, 2-1-7 Fukushima, Fukushima-ku, Osaka City, Osaka 553-0003, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Kuroe
authors.forename: Ataru
authors.initials: A
authors.lastname: Taniuguchi
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Fukushima
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Nakai
authors.forename: Minako
authors.initials: M
authors.lastname: Ohgushi
authors.forename: Michihiro
authors.initials: M
authors.lastname: Ohya
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Seino
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D001786:Blood Glucose; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004341:Drug Evaluation; D004487:Edema / Q000139:chemically induced / Q000209:etiology; D005076:Exanthema / Q000139:chemically induced / Q000209:etiology; D005221:Fatigue / Q000139:chemically induced / Q000209:etiology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D007564:Japan; D007866:Leg / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin